Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Evoke Pharma ( (EVOK) ) is now available.
On February 20, 2025, Evoke Pharma appointed Greg Pyszcymuka as a Class I director, with his term expiring at the 2026 annual meeting of stockholders. This appointment is part of a strategic move to strengthen the company’s leadership, with Mr. Pyszcymuka bringing over 20 years of experience in sales, marketing, and commercial operations from his previous roles at Aytu Biopharma, Neos Therapeutics, and other pharmaceutical companies. His appointment is expected to enhance Evoke Pharma’s governance and operational strategies.
More about Evoke Pharma
YTD Price Performance: 13.42%
Average Trading Volume: 20,085
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $7.53M
Learn more about EVOK stock on TipRanks’ Stock Analysis page.